• Please log in or register to access this feature.

Viral Hepatitis

You have full text access to this OnlineOpen article

IP-10 predicts viral response and therapeutic outcome in difficult-to-treat patients with HCV genotype 1 infection†

  1. Martin Lagging1,‡,*,
  2. Ana I. Romero1,
  3. Johan Westin1,
  4. Gunnar Norkrans1,
  5. Amar P. Dhillon2,
  6. Jean-Michel Pawlotsky3,†,
  7. Stefan Zeuzem4,†,
  8. Michael von Wagner4,
  9. Francesco Negro5,
  10. Solko W. Schalm6,
  11. Bart L. Haagmans7,
  12. Carlo Ferrari8,
  13. Gabriele Missale8,
  14. Avidan U. Neumann9,†,
  15. Elke Verheij-Hart6,
  16. Kristoffer Hellstrand1,†

Article first published online: 28 NOV 2006

DOI: 10.1002/hep.21407

Issue

Hepatology

Hepatology

Volume 44, Issue 6, pages 1617–1625, December 2006

Additional Information

How to Cite

Lagging, M., Romero, A. I., Westin, J., Norkrans, G., Dhillon, A. P., Pawlotsky, J.-M., Zeuzem, S., von Wagner, M., Negro, F., Schalm, S. W., Haagmans, B. L., Ferrari, C., Missale, G., Neumann, A. U., Verheij-Hart, E. and Hellstrand, K. (2006), IP-10 predicts viral response and therapeutic outcome in difficult-to-treat patients with HCV genotype 1 infection. Hepatology, 44: 1617–1625. doi: 10.1002/hep.21407

Author Information

  1. 1

    Department of Infectious Diseases, University of Göteborg, Sweden

  2. 2

    Department of Histopathology, Royal Free Hospital, London, UK

  3. 3

    Hôpital Henri Mondor–Université Paris XII, Creteil, France

  4. 4

    Saarland University Hospital, Homburg/Saar, Germany

  5. 5

    Hospital University of Genève, Genève, Switzerland

  6. 6

    University Hospital Rotterdam Dijkzigt, Rotterdam, Netherlands

  7. 7

    Department of Virology, Erasmus MC, Rotterdam

  8. 8

    Azienda Ospedaliera di Parma, Parma, Italy

  9. 9

    Bar-Ilan University, Ramat-Gan, Israel

  1. †

    Potential conflict of interest: Dr. Pawlotsky is a consultant for, advises, and received grants from Gilead, Roche, Schering-Plough, and Vertex. He also received grants from Isis and Prometheus Lab. He is a consultant and advises for Abbott, Akors, Bristol-Myers Squibb, GlaxoSmithKline, Human Genome Sciences, Idenix, Idun Pharmaceuticals, InterMune, Novartis, Valeant, and XTL Biopharmaceuticals. Dr. Zeuzem is a consultant for, advises, is on the speakers' bureau of, and received grants from Schering-Plough and Roche. Dr. Hellstrand owns stock in, advises, and holds intellectual property rights with Epicept. Dr. Neumann is on the speaker's bureau of and received grants from Roche. He is on the speakers' bureau of Schering-Plough. He advises for, received grants, and is on the speaker's bureau of HGSI.

  2. ‡

    fax: (46) 31-41-12-56

*Department of Infectious Diseases, Göteborg University, Guldhedsgatan 10B, SE-413 46 Göteborg, Sweden

  1. †

    Potential conflict of interest: Dr. Pawlotsky is a consultant for, advises, and received grants from Gilead, Roche, Schering-Plough, and Vertex. He also received grants from Isis and Prometheus Lab. He is a consultant and advises for Abbott, Akors, Bristol-Myers Squibb, GlaxoSmithKline, Human Genome Sciences, Idenix, Idun Pharmaceuticals, InterMune, Novartis, Valeant, and XTL Biopharmaceuticals. Dr. Zeuzem is a consultant for, advises, is on the speakers' bureau of, and received grants from Schering-Plough and Roche. Dr. Hellstrand owns stock in, advises, and holds intellectual property rights with Epicept. Dr. Neumann is on the speaker's bureau of and received grants from Roche. He is on the speakers' bureau of Schering-Plough. He advises for, received grants, and is on the speaker's bureau of HGSI.

  2. ‡

    fax: (46) 31-41-12-56

Publication History

  1. Issue published online: 28 NOV 2006
  2. Article first published online: 28 NOV 2006
  3. Manuscript Accepted: 6 SEP 2006
  4. Manuscript Received: 7 APR 2006

Funded by

  • European Community. Grant Number: QLK2-2000-00836
  • The Swedish Society Against Cancer (Cancerfonden)
  • Hoffmann-La Roche
  • Inga-Britt & Arne Lundberg Foundation
  • Swedish Society of Medicine
  • EpiCept Corporation

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (540K)

Abstract

Plasma from 173 patients with HCV genotype 1 infection was analyzed for IP-10 levels prior to treatment with pegylated interferon-α-2a and ribavirin. Significantly lower IP-10 levels were observed in patients achieving a rapid viral response (RVR) (P < .0001), even in those with body mass index (BMI) ≥ 25 kg/m2 (P = .004) and with baseline viral load ≥ 2 million IU/mL (P = .001). Similarly, significantly lower IP-10 levels were observed in patients obtaining a sustained viral response (SVR) (P = .0002), including those having higher BMI (P < .05), higher viral load (P = .0005), and both higher BMI and viral load (P < .03). In multivariate logistic regression analyses, a low IP-10 value was independently predictive of both RVR and SVR. A baseline cutoff IP-10 value of 600 pg/mL yielded a negative predictive value (NPV) of 79% (19/24) for all genotype 1–infected patients, which was comparable with that observed using a reduction in HCV-RNA by at least 2 logs after 12 weeks of therapy (NPV 86%; 19/22); by combining the two, 30 of 38 patients (NPV 79%) potentially could have been spared unnecessary therapy. In patients having both higher BMI and viral load, cut-off levels of 150 and 600 pg/mL yielded a positive predictive value (PPV) of 71% and NPV of 100%, respectively. In conclusion, pretreatment IP-10 levels predict RVR and SVR in patients infected with HCV genotype 1, even in those with higher BMI and viral load. A substantial proportion of the latter patients may achieve SVR in spite of unfavorable baseline characteristics if their pretreatment IP-10 level is low. Thus, pretreatment IP-10 analysis may prove helpful in decision-making regarding pharmaceutical intervention. (HEPATOLOGY 2006;44:1617–1625.)

View Full Article (HTML) Get PDF (540K)